Does Spironolactone Have a Dose‐Dependent Effect on Left Ventricular Remodeling in Patients with Preserved Left Ventricular Function After an Acute Myocardial Infarction?
Summary Aims The aim of this study was to investigate the effects of spironolactone on left ventricular (LV) remodeling in patients with preserved LV function following acute myocardial infarction (AMI). Methods and Results Successfully revascularized patients (n = 186) with acute ST elevation MI (S...
Gespeichert in:
| Veröffentlicht in: | Cardiovascular therapeutics 2013-08, Vol.31 (4), p.224-229 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 229 |
|---|---|
| container_issue | 4 |
| container_start_page | 224 |
| container_title | Cardiovascular therapeutics |
| container_volume | 31 |
| creator | Vatankulu, Mehmet Akif Bacaksiz, Ahmet Sonmez, Osman Alihanoglu, Yusuf Koc, Fatih Demir, Kenan Gul, Enes Elvin Turfan, Murat Tasal, Abdurrahman Kayrak, Mehmet Yazici, Mehmet Ozdemir, Kurtulus |
| description | Summary
Aims
The aim of this study was to investigate the effects of spironolactone on left ventricular (LV) remodeling in patients with preserved LV function following acute myocardial infarction (AMI).
Methods and Results
Successfully revascularized patients (n = 186) with acute ST elevation MI (STEMI) were included in the study. Patients were randomly divided into three groups, each of which was administered a different dose of spironolactone (12.5, 25 mg, or none). Echocardiography was performed within the first 3 days and at 6 months after MI. Echocardiography control was performed on 160 patients at a 6‐month follow‐up. The median left ventricular ejection fraction (LVEF) increased significantly in all groups, but no significant difference was observed between groups (P = 0.13). At the end of the sixth month, the myocardial performance index (MPI) had improved in each of the three groups, but no significant difference was found between groups (F = 2.00, P = 0.15). The mean LV peak systolic velocities (Sm) increased only in the control group during the follow‐up period, but there is no significant difference between groups (F = 1.79, P = 0.18). The left ventricular end‐systolic volume index (LVESVI) and the left ventricular end‐diastolic volume index (LVEDVI) did not change significantly compared with the basal values between groups (F = 0.05, P = 0.81 and F = 1.03, P = 0.31, respectively).
Conclusion
In conclusion, spironolactone dosages of up to 25 mg do not augment optimal medical treatment for LV remodeling in patients with preserved cardiac functions after AMI. |
| doi_str_mv | 10.1111/1755-5922.12006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_24P</sourceid><recordid>TN_cdi_proquest_miscellaneous_1406178168</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1406178168</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4426-a115954f786d1eeb68e986f52eb4a5835fec564959bda20703fc6cc6f34fb5bc3</originalsourceid><addsrcrecordid>eNqFkc9uEzEQxlcIREvhzA1ZQkhc0tq7a-_uCVVJSysFUZU_V2vWOwZXjp3a3la58Qh9kD4VT4LThCDBgbnMaPybb8b6iuIlo4csxxFrOJ_wriwPWUmpeFTs7zqPdzWr94pnMV5lgHaCPS32yrITFadiv7ifeYzk09IE77wFlbxDcgY3SIDMfMSfP-5muEQ3oEvkRGtUiXhH5qgT-Zp7wajRQiCXuPADWuO-EePIBSSTHyO5Nek7uQgYMdzg8O_Y6ehUMlnwWCcMBHKhxoTkw8orCIMBS86dhvAAvXtePNFgI77Y5oPiy-nJ5-nZZP7x_fn0eD5RdV2KCTDGO17rphUDQ-xFi10rNC-xr4G3Fc-_4KLueNcPUNKGVloJpYSuat3zXlUHxduN7jL46xFjkgsTFVoLDv0YJaupYE3LRJvR13-hV34MLl-3pmjLOaM0U0cbSgUfY0Atl8EsIKwko3JtpFxbJde2yQcj88Srre7YL3DY8b-dy8CbLQBRgdUBnDLxD9fwvL5jmeMb7tZYXP1vr5zOLjcH_AK0kLdB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1400855100</pqid></control><display><type>article</type><title>Does Spironolactone Have a Dose‐Dependent Effect on Left Ventricular Remodeling in Patients with Preserved Left Ventricular Function After an Acute Myocardial Infarction?</title><source>Wiley Online Library Open Access</source><creator>Vatankulu, Mehmet Akif ; Bacaksiz, Ahmet ; Sonmez, Osman ; Alihanoglu, Yusuf ; Koc, Fatih ; Demir, Kenan ; Gul, Enes Elvin ; Turfan, Murat ; Tasal, Abdurrahman ; Kayrak, Mehmet ; Yazici, Mehmet ; Ozdemir, Kurtulus</creator><creatorcontrib>Vatankulu, Mehmet Akif ; Bacaksiz, Ahmet ; Sonmez, Osman ; Alihanoglu, Yusuf ; Koc, Fatih ; Demir, Kenan ; Gul, Enes Elvin ; Turfan, Murat ; Tasal, Abdurrahman ; Kayrak, Mehmet ; Yazici, Mehmet ; Ozdemir, Kurtulus</creatorcontrib><description>Summary
Aims
The aim of this study was to investigate the effects of spironolactone on left ventricular (LV) remodeling in patients with preserved LV function following acute myocardial infarction (AMI).
Methods and Results
Successfully revascularized patients (n = 186) with acute ST elevation MI (STEMI) were included in the study. Patients were randomly divided into three groups, each of which was administered a different dose of spironolactone (12.5, 25 mg, or none). Echocardiography was performed within the first 3 days and at 6 months after MI. Echocardiography control was performed on 160 patients at a 6‐month follow‐up. The median left ventricular ejection fraction (LVEF) increased significantly in all groups, but no significant difference was observed between groups (P = 0.13). At the end of the sixth month, the myocardial performance index (MPI) had improved in each of the three groups, but no significant difference was found between groups (F = 2.00, P = 0.15). The mean LV peak systolic velocities (Sm) increased only in the control group during the follow‐up period, but there is no significant difference between groups (F = 1.79, P = 0.18). The left ventricular end‐systolic volume index (LVESVI) and the left ventricular end‐diastolic volume index (LVEDVI) did not change significantly compared with the basal values between groups (F = 0.05, P = 0.81 and F = 1.03, P = 0.31, respectively).
Conclusion
In conclusion, spironolactone dosages of up to 25 mg do not augment optimal medical treatment for LV remodeling in patients with preserved cardiac functions after AMI.</description><identifier>ISSN: 1755-5914</identifier><identifier>EISSN: 1755-5922</identifier><identifier>DOI: 10.1111/1755-5922.12006</identifier><identifier>PMID: 22963506</identifier><language>eng</language><publisher>Oxford: Blackwell</publisher><subject>Adult ; Aged ; Aldosterone ; Analysis of Variance ; Biological and medical sciences ; Cardiology. Vascular system ; Cardiovascular system ; Chi-Square Distribution ; Coronary heart disease ; Dose-Response Relationship, Drug ; Echocardiography, Doppler ; Female ; Heart ; Humans ; Male ; Medical sciences ; Middle Aged ; Mineralocorticoid Receptor Antagonists - administration & dosage ; Myocardial Contraction ; Myocardial infarction ; Myocardial Infarction - diagnosis ; Myocardial Infarction - diagnostic imaging ; Myocardial Infarction - drug therapy ; Myocardial Infarction - physiopathology ; Myocarditis. Cardiomyopathies ; Pharmacology. Drug treatments ; Preserved ejection fraction ; Prospective Studies ; Remodeling ; Spironolactone ; Spironolactone - administration & dosage ; Stroke Volume ; Time Factors ; Treatment Outcome ; Turkey ; Ventricular Function, Left ; Ventricular Remodeling - drug effects</subject><ispartof>Cardiovascular therapeutics, 2013-08, Vol.31 (4), p.224-229</ispartof><rights>2012 John Wiley & Sons Ltd</rights><rights>2014 INIST-CNRS</rights><rights>2012 John Wiley & Sons Ltd.</rights><rights>Copyright © 2013 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4426-a115954f786d1eeb68e986f52eb4a5835fec564959bda20703fc6cc6f34fb5bc3</citedby><cites>FETCH-LOGICAL-c4426-a115954f786d1eeb68e986f52eb4a5835fec564959bda20703fc6cc6f34fb5bc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2F1755-5922.12006$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2F1755-5922.12006$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1427,11541,27901,27902,46027,46384,46451,46808</link.rule.ids><linktorsrc>$$Uhttps://onlinelibrary.wiley.com/doi/abs/10.1111%2F1755-5922.12006$$EView_record_in_Wiley-Blackwell$$FView_record_in_$$GWiley-Blackwell</linktorsrc><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27540091$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22963506$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vatankulu, Mehmet Akif</creatorcontrib><creatorcontrib>Bacaksiz, Ahmet</creatorcontrib><creatorcontrib>Sonmez, Osman</creatorcontrib><creatorcontrib>Alihanoglu, Yusuf</creatorcontrib><creatorcontrib>Koc, Fatih</creatorcontrib><creatorcontrib>Demir, Kenan</creatorcontrib><creatorcontrib>Gul, Enes Elvin</creatorcontrib><creatorcontrib>Turfan, Murat</creatorcontrib><creatorcontrib>Tasal, Abdurrahman</creatorcontrib><creatorcontrib>Kayrak, Mehmet</creatorcontrib><creatorcontrib>Yazici, Mehmet</creatorcontrib><creatorcontrib>Ozdemir, Kurtulus</creatorcontrib><title>Does Spironolactone Have a Dose‐Dependent Effect on Left Ventricular Remodeling in Patients with Preserved Left Ventricular Function After an Acute Myocardial Infarction?</title><title>Cardiovascular therapeutics</title><addtitle>Cardiovasc Ther</addtitle><description>Summary
Aims
The aim of this study was to investigate the effects of spironolactone on left ventricular (LV) remodeling in patients with preserved LV function following acute myocardial infarction (AMI).
Methods and Results
Successfully revascularized patients (n = 186) with acute ST elevation MI (STEMI) were included in the study. Patients were randomly divided into three groups, each of which was administered a different dose of spironolactone (12.5, 25 mg, or none). Echocardiography was performed within the first 3 days and at 6 months after MI. Echocardiography control was performed on 160 patients at a 6‐month follow‐up. The median left ventricular ejection fraction (LVEF) increased significantly in all groups, but no significant difference was observed between groups (P = 0.13). At the end of the sixth month, the myocardial performance index (MPI) had improved in each of the three groups, but no significant difference was found between groups (F = 2.00, P = 0.15). The mean LV peak systolic velocities (Sm) increased only in the control group during the follow‐up period, but there is no significant difference between groups (F = 1.79, P = 0.18). The left ventricular end‐systolic volume index (LVESVI) and the left ventricular end‐diastolic volume index (LVEDVI) did not change significantly compared with the basal values between groups (F = 0.05, P = 0.81 and F = 1.03, P = 0.31, respectively).
Conclusion
In conclusion, spironolactone dosages of up to 25 mg do not augment optimal medical treatment for LV remodeling in patients with preserved cardiac functions after AMI.</description><subject>Adult</subject><subject>Aged</subject><subject>Aldosterone</subject><subject>Analysis of Variance</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular system</subject><subject>Chi-Square Distribution</subject><subject>Coronary heart disease</subject><subject>Dose-Response Relationship, Drug</subject><subject>Echocardiography, Doppler</subject><subject>Female</subject><subject>Heart</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mineralocorticoid Receptor Antagonists - administration & dosage</subject><subject>Myocardial Contraction</subject><subject>Myocardial infarction</subject><subject>Myocardial Infarction - diagnosis</subject><subject>Myocardial Infarction - diagnostic imaging</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Myocardial Infarction - physiopathology</subject><subject>Myocarditis. Cardiomyopathies</subject><subject>Pharmacology. Drug treatments</subject><subject>Preserved ejection fraction</subject><subject>Prospective Studies</subject><subject>Remodeling</subject><subject>Spironolactone</subject><subject>Spironolactone - administration & dosage</subject><subject>Stroke Volume</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Turkey</subject><subject>Ventricular Function, Left</subject><subject>Ventricular Remodeling - drug effects</subject><issn>1755-5914</issn><issn>1755-5922</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9uEzEQxlcIREvhzA1ZQkhc0tq7a-_uCVVJSysFUZU_V2vWOwZXjp3a3la58Qh9kD4VT4LThCDBgbnMaPybb8b6iuIlo4csxxFrOJ_wriwPWUmpeFTs7zqPdzWr94pnMV5lgHaCPS32yrITFadiv7ifeYzk09IE77wFlbxDcgY3SIDMfMSfP-5muEQ3oEvkRGtUiXhH5qgT-Zp7wajRQiCXuPADWuO-EePIBSSTHyO5Nek7uQgYMdzg8O_Y6ehUMlnwWCcMBHKhxoTkw8orCIMBS86dhvAAvXtePNFgI77Y5oPiy-nJ5-nZZP7x_fn0eD5RdV2KCTDGO17rphUDQ-xFi10rNC-xr4G3Fc-_4KLueNcPUNKGVloJpYSuat3zXlUHxduN7jL46xFjkgsTFVoLDv0YJaupYE3LRJvR13-hV34MLl-3pmjLOaM0U0cbSgUfY0Atl8EsIKwko3JtpFxbJde2yQcj88Srre7YL3DY8b-dy8CbLQBRgdUBnDLxD9fwvL5jmeMb7tZYXP1vr5zOLjcH_AK0kLdB</recordid><startdate>201308</startdate><enddate>201308</enddate><creator>Vatankulu, Mehmet Akif</creator><creator>Bacaksiz, Ahmet</creator><creator>Sonmez, Osman</creator><creator>Alihanoglu, Yusuf</creator><creator>Koc, Fatih</creator><creator>Demir, Kenan</creator><creator>Gul, Enes Elvin</creator><creator>Turfan, Murat</creator><creator>Tasal, Abdurrahman</creator><creator>Kayrak, Mehmet</creator><creator>Yazici, Mehmet</creator><creator>Ozdemir, Kurtulus</creator><general>Blackwell</general><general>Hindawi Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201308</creationdate><title>Does Spironolactone Have a Dose‐Dependent Effect on Left Ventricular Remodeling in Patients with Preserved Left Ventricular Function After an Acute Myocardial Infarction?</title><author>Vatankulu, Mehmet Akif ; Bacaksiz, Ahmet ; Sonmez, Osman ; Alihanoglu, Yusuf ; Koc, Fatih ; Demir, Kenan ; Gul, Enes Elvin ; Turfan, Murat ; Tasal, Abdurrahman ; Kayrak, Mehmet ; Yazici, Mehmet ; Ozdemir, Kurtulus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4426-a115954f786d1eeb68e986f52eb4a5835fec564959bda20703fc6cc6f34fb5bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aldosterone</topic><topic>Analysis of Variance</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular system</topic><topic>Chi-Square Distribution</topic><topic>Coronary heart disease</topic><topic>Dose-Response Relationship, Drug</topic><topic>Echocardiography, Doppler</topic><topic>Female</topic><topic>Heart</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mineralocorticoid Receptor Antagonists - administration & dosage</topic><topic>Myocardial Contraction</topic><topic>Myocardial infarction</topic><topic>Myocardial Infarction - diagnosis</topic><topic>Myocardial Infarction - diagnostic imaging</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Myocardial Infarction - physiopathology</topic><topic>Myocarditis. Cardiomyopathies</topic><topic>Pharmacology. Drug treatments</topic><topic>Preserved ejection fraction</topic><topic>Prospective Studies</topic><topic>Remodeling</topic><topic>Spironolactone</topic><topic>Spironolactone - administration & dosage</topic><topic>Stroke Volume</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Turkey</topic><topic>Ventricular Function, Left</topic><topic>Ventricular Remodeling - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vatankulu, Mehmet Akif</creatorcontrib><creatorcontrib>Bacaksiz, Ahmet</creatorcontrib><creatorcontrib>Sonmez, Osman</creatorcontrib><creatorcontrib>Alihanoglu, Yusuf</creatorcontrib><creatorcontrib>Koc, Fatih</creatorcontrib><creatorcontrib>Demir, Kenan</creatorcontrib><creatorcontrib>Gul, Enes Elvin</creatorcontrib><creatorcontrib>Turfan, Murat</creatorcontrib><creatorcontrib>Tasal, Abdurrahman</creatorcontrib><creatorcontrib>Kayrak, Mehmet</creatorcontrib><creatorcontrib>Yazici, Mehmet</creatorcontrib><creatorcontrib>Ozdemir, Kurtulus</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiovascular therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Vatankulu, Mehmet Akif</au><au>Bacaksiz, Ahmet</au><au>Sonmez, Osman</au><au>Alihanoglu, Yusuf</au><au>Koc, Fatih</au><au>Demir, Kenan</au><au>Gul, Enes Elvin</au><au>Turfan, Murat</au><au>Tasal, Abdurrahman</au><au>Kayrak, Mehmet</au><au>Yazici, Mehmet</au><au>Ozdemir, Kurtulus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Does Spironolactone Have a Dose‐Dependent Effect on Left Ventricular Remodeling in Patients with Preserved Left Ventricular Function After an Acute Myocardial Infarction?</atitle><jtitle>Cardiovascular therapeutics</jtitle><addtitle>Cardiovasc Ther</addtitle><date>2013-08</date><risdate>2013</risdate><volume>31</volume><issue>4</issue><spage>224</spage><epage>229</epage><pages>224-229</pages><issn>1755-5914</issn><eissn>1755-5922</eissn><abstract>Summary
Aims
The aim of this study was to investigate the effects of spironolactone on left ventricular (LV) remodeling in patients with preserved LV function following acute myocardial infarction (AMI).
Methods and Results
Successfully revascularized patients (n = 186) with acute ST elevation MI (STEMI) were included in the study. Patients were randomly divided into three groups, each of which was administered a different dose of spironolactone (12.5, 25 mg, or none). Echocardiography was performed within the first 3 days and at 6 months after MI. Echocardiography control was performed on 160 patients at a 6‐month follow‐up. The median left ventricular ejection fraction (LVEF) increased significantly in all groups, but no significant difference was observed between groups (P = 0.13). At the end of the sixth month, the myocardial performance index (MPI) had improved in each of the three groups, but no significant difference was found between groups (F = 2.00, P = 0.15). The mean LV peak systolic velocities (Sm) increased only in the control group during the follow‐up period, but there is no significant difference between groups (F = 1.79, P = 0.18). The left ventricular end‐systolic volume index (LVESVI) and the left ventricular end‐diastolic volume index (LVEDVI) did not change significantly compared with the basal values between groups (F = 0.05, P = 0.81 and F = 1.03, P = 0.31, respectively).
Conclusion
In conclusion, spironolactone dosages of up to 25 mg do not augment optimal medical treatment for LV remodeling in patients with preserved cardiac functions after AMI.</abstract><cop>Oxford</cop><pub>Blackwell</pub><pmid>22963506</pmid><doi>10.1111/1755-5922.12006</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 1755-5914 |
| ispartof | Cardiovascular therapeutics, 2013-08, Vol.31 (4), p.224-229 |
| issn | 1755-5914 1755-5922 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1406178168 |
| source | Wiley Online Library Open Access |
| subjects | Adult Aged Aldosterone Analysis of Variance Biological and medical sciences Cardiology. Vascular system Cardiovascular system Chi-Square Distribution Coronary heart disease Dose-Response Relationship, Drug Echocardiography, Doppler Female Heart Humans Male Medical sciences Middle Aged Mineralocorticoid Receptor Antagonists - administration & dosage Myocardial Contraction Myocardial infarction Myocardial Infarction - diagnosis Myocardial Infarction - diagnostic imaging Myocardial Infarction - drug therapy Myocardial Infarction - physiopathology Myocarditis. Cardiomyopathies Pharmacology. Drug treatments Preserved ejection fraction Prospective Studies Remodeling Spironolactone Spironolactone - administration & dosage Stroke Volume Time Factors Treatment Outcome Turkey Ventricular Function, Left Ventricular Remodeling - drug effects |
| title | Does Spironolactone Have a Dose‐Dependent Effect on Left Ventricular Remodeling in Patients with Preserved Left Ventricular Function After an Acute Myocardial Infarction? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T16%3A19%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_24P&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Does%20Spironolactone%20Have%20a%20Dose%E2%80%90Dependent%20Effect%20on%20Left%20Ventricular%20Remodeling%20in%20Patients%20with%20Preserved%20Left%20Ventricular%20Function%20After%20an%20Acute%20Myocardial%20Infarction?&rft.jtitle=Cardiovascular%20therapeutics&rft.au=Vatankulu,%20Mehmet%20Akif&rft.date=2013-08&rft.volume=31&rft.issue=4&rft.spage=224&rft.epage=229&rft.pages=224-229&rft.issn=1755-5914&rft.eissn=1755-5922&rft_id=info:doi/10.1111/1755-5922.12006&rft_dat=%3Cproquest_24P%3E1406178168%3C/proquest_24P%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1400855100&rft_id=info:pmid/22963506&rfr_iscdi=true |